Codexis to Present at 2013 BIO International Convention

  Codexis to Present at 2013 BIO International Convention

2013 BIO International Convention

Business Wire

REDWOOD CITY, Calif. -- April 22, 2013

Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for
pharmaceutical, biofuel and chemical production, announced today that Gjalt
Huisman, Ph.D., Vice President, Pharmaceutical R&D at Codexis, will present at
the 2013 BIO International Convention in Chicago, IL, on Tuesday, April 23,
2013. Dr. Huisman will present an overview of the company's application of its
CodeEvolver^® directed evolution technology platform in the field of enzyme
therapeutics.

“Codexis’ technology has revolutionized the manufacture of pharmaceuticals and
is currently used in the production of some of the world's bestselling drugs.
We are now applying our advanced technology to generate new and improved
biologic therapeutics,” said Dr. Huisman. “Now that we have established the
core value that our technology brings, we are excited to apply our technology
platform as the operating system to generate new and improved therapeutic
enzymes in a broad array of applications. We may evaluate opportunities in a
number of therapeutics areas, such as enzyme replacement, metabolic pool
depletion, celiac disease and antibody therapies.”

Event: 2013 BIO International Convention's BIO Business Forum
Date: Tuesday, April 23, 2013
Time: 8:15 a.m. Central Time
Location: Chicago Bulls Room; McCormick Place Convention Center; Chicago, IL

About Codexis, Inc.

Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical
production. Codexis’ proven technology enables scale-up and implementation of
biocatalytic solutions to meet customer needs for rapid, cost-effective and
sustainable process development – from research to manufacturing. For more
information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to Codexis’
ability to deploy its technology platform to generate new and improved
therapeutic enzymes. You should not place undue reliance on these
forward-looking statements because they involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond Codexis’
control and that could materially affect actual results. Factors that could
materially affect actual results include Codexis’ need for substantial
additional capital in the future in order to expand its business; Codexis’
dependence on its collaborators; potential adverse effects to Codexis’
business if its customers’ pharmaceutical products are not received well in
the markets; Codexis’ ability to develop and commercialize new products for
the pharmaceutical markets; and Codexis’ ability to deploy its technology
platform in new adjacent market spaces. Additional factors that could
materially affect actual results can be found in Codexis’ Annual Report on
Form 10-K for the period ended December 31, 2012 filed with the Securities and
Exchange Commission on April 2, 2013, including under the caption “Risk
Factors.” Codexis expressly disclaims any intent or obligation to update these
forward-looking statements, except as required by law.

Contact:

For Codexis, Inc.
Media
Jemma Connor, +44 161 359 3255
jemma.connor@notchcommunications.co.uk
or
Investors
Paul Cox, 212-362-1200
ir@codexis.com
 
Press spacebar to pause and continue. Press esc to stop.